COMMUNIQUÉS West-GlobeNewswire

Crossject : Information relative au nombre total de droits de vote et d'actions composant le capital social
10/04/2024
Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 10 avril 2024 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ), « specialty pharma » qui développe et [...]
Acryno To Blends AI and Luxury Concierge Services to Reimagine Healthcare
10/04/2024
The novel platform seeks to match patients with skilled medical experts to democratize access to quality providers and cut down on wait times for care NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- In an era of rising [...]
NeuroOne® CEO Dave Rosa Featured on Bloomberg Technology
10/04/2024
EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and [...]
Avicanna Announces Completion of Topical Gel Observational Real-World Evidence Study
10/04/2024
The study results revealed improvements in symptoms and quality of life in patients with musculoskeletal pain and inflammation TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company [...]
Joint Statement Applauding Final Rule for Web Accessibility Under Title II of the ADA
10/04/2024
WASHINGTON, April 10, 2024 (GLOBE NEWSWIRE) -- The American Council of the Blind (ACB), the American Foundation for the Blind (AFB), the National Disability Rights Network (NDRN), and the National Federation of the [...]
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
10/04/2024
Lack of early symptom improvement is not predictive of final responder status MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, [...]
Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder
10/04/2024
Findings underscore the liver safety of AD04 as compared to placebo in the prior Phase 3 clinical trial GLEN ALLEN, Va., April 10, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “ [...]
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
10/04/2024
MISSISSAUGA, Ontario, April 10, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor [...]
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10/04/2024
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at the 2024 Bloom [...]
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
10/04/2024
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS ( [...]
Nexalin Technology CEO Provides Letter to Shareholders
10/04/2024
Reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model HOUSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. ( [...]
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
10/04/2024
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in [...]
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
10/04/2024
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. ( [...]
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
10/04/2024
ROCKVILLE, Md., April 10, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
10/04/2024
WILMETTE, Ill., April 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced [...]
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
10/04/2024
Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster [...]
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
10/04/2024
450-Bed Hospital Purchases BVA-100 ™ Blood Volume Analyzer to Launch H eart Failure P rogram Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume [...]
Elucent Medical Secures Series C Funding to Advance Oncologic Surgery Innovation
10/04/2024
EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- Elucent Medical, a pioneering medical technology company transforming the field of surgical navigation through In-Site Spatial Intelligence (iSI) is pleased to [...]
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
10/04/2024
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management [...]

Pages